2020
Time Since Infection and Risks of Future Disease for Individuals with Mycobacterium tuberculosis Infection in the United States
Menzies NA, Swartwood N, Testa C, Malyuta Y, Hill AN, Marks SM, Cohen T, Salomon JA. Time Since Infection and Risks of Future Disease for Individuals with Mycobacterium tuberculosis Infection in the United States. Epidemiology 2020, 32: 70-78. PMID: 33009253, PMCID: PMC7707158, DOI: 10.1097/ede.0000000000001271.Peer-Reviewed Original ResearchConceptsLatent TB infectionMycobacterium tuberculosis infectionTB infectionTuberculosis infectionTB natural historyRisk of tuberculosisMost TB casesRate of progressionYounger age groupsLower future riskTransmission dynamic modelTB casesTB riskPrevalent infectionProgression riskLifetime riskRisk factorsIncidence trendsClinical diseaseCumulative riskGeneral populationAverage ageNew infectionsUS populationAge groups
2017
Protective effects of household-based TB interventions are robust to neighbourhood-level variation in exposure risk in Lima, Peru: a model-based analysis
Zelner J, Murray M, Becerra M, Galea J, Lecca L, Calderon R, Yataco R, Zhang Z, Cohen T. Protective effects of household-based TB interventions are robust to neighbourhood-level variation in exposure risk in Lima, Peru: a model-based analysis. International Journal Of Epidemiology 2017, 47: 185-192. PMID: 29025111, DOI: 10.1093/ije/dyx171.Peer-Reviewed Original ResearchConceptsIsoniazid preventive therapyLatent TB infectionTB casesHousehold contactsHousehold exposureTB diseaseHealth centersPopulation-based prospective cohort studyHigh-risk household contactsMore casesBlanket screeningIncident pulmonary tuberculosisIncident TB diseasePositive household contactsProspective cohort studyTB screening programPublic Health CenterIncident tuberculosisTB infectionCohort studyPreventive therapyPulmonary tuberculosisTB incidenceSkin testTB risk
2016
Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic
Kunkel A, Crawford FW, Shepherd J, Cohen T. Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic. AIDS 2016, 30: 2715-2723. PMID: 27782966, PMCID: PMC5089846, DOI: 10.1097/qad.0000000000001235.Peer-Reviewed Original ResearchConceptsContinuous isoniazid preventive therapyIsoniazid preventive therapyIsoniazid-resistant tuberculosisTB epidemicPreventive therapyEffective TB treatmentLatent TB infectionTB drug resistanceTransmission dynamic modelTB infectionMortality benefitTB treatmentHIV controlHIV incidenceTB incidenceTB transmissionCase findingDrug resistanceIncidenceTuberculosisInitial benefitPLHIVHIVTherapyEpidemic
2014
Bacillus Calmette-Guérin and Isoniazid Preventive Therapy Protect Contacts of Patients with Tuberculosis
Zelner JL, Murray MB, Becerra MC, Galea J, Lecca L, Calderon R, Yataco R, Contreras C, Zhang Z, Grenfell BT, Cohen T. Bacillus Calmette-Guérin and Isoniazid Preventive Therapy Protect Contacts of Patients with Tuberculosis. American Journal Of Respiratory And Critical Care Medicine 2014, 189: 853-859. PMID: 24592878, PMCID: PMC4225829, DOI: 10.1164/rccm.201310-1896oc.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsAgedAged, 80 and overAntitubercular AgentsBCG VaccineChildChild, PreschoolContact TracingFemaleFollow-Up StudiesHumansInfantIsoniazidMaleMiddle AgedModels, StatisticalModels, TheoreticalMultivariate AnalysisOdds RatioPeruProspective StudiesTreatment OutcomeTuberculosis, PulmonaryYoung AdultConceptsIsoniazid preventive therapyAge-specific efficacyLatent TB infectionIncident tuberculosisHousehold contactsTB diseaseTB infectionPulmonary tuberculosisRisk ratioUse of IPTObservational prospective cohort studyBacillus Calmette-Guérin (BCG) vaccinationHigh TB burden settingsAdditional TB casesHIV-positive contactsIncident pulmonary tuberculosisHIV-negative childrenProspective cohort studyPublic Health CenterBacillus Calmette-GuérinYear-long followWorld Health OrganizationCohort studyPreventive therapyTB cases